Drug intelligence / Profile preview

LG203003

Development stage: Unknown
Lead developer: LG Chem
Modality: Small Molecules

Overview

LG203003 is an investigational small molecule diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor being developed by LG Chem for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). By selectively inhibiting DGAT2, a key enzyme in triglyceride synthesis, the drug aims to suppress fat accumulation in liver cells, thereby reducing liver damage, inflammation, and fibrosis. LG203003 is LG Chem's second NASH candidate and entered Phase 1 clinical trials in 2022 to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and patients with NAFLD.

Targets

DGAT2 (Hepatic diacylglycerol acyltransferase 2)

Beyond the preview

Go deeper on LG203003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LG203003.

Explore the full profile